推薦產品
生物源
mouse
品質等級
100
500
共軛
unconjugated
抗體表格
culture supernatant
抗體產品種類
primary antibodies
無性繁殖
MRQ-36, monoclonal
描述
For In Vitro Diagnostic Use in Select Regions (See Chart)
形狀
buffered aqueous solution
物種活性
human
包裝
vial of 0.1 mL concentrate (119M-14)
vial of 0.5 mL concentrate (119M-15)
bottle of 1.0 mL predilute (119M-17)
vial of 1.0 mL concentrate (119M-16)
bottle of 7.0 mL predilute (119M-18)
製造商／商標名
Cell Marque®
技術
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
同型
IgG1κ
控制
tonsil
運輸包裝
wet ice
儲存溫度
2-8°C
視覺化
membranous
基因資訊
human ... CD19(930)
一般說明
CD19 is present in both normal and malignant B-cells and has long been considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, mantle zone cells, and scattered cells in the interfollicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, CD19 is also expressed in immature B-cells; although recent studies have described CD19 loss in a few B-cell neoplasms.
品質
 IVD |  IVD |  IVD |  RUO |
聯結
CD19 Positive Control Slides, Product No. 119S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
準備報告
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
其他說明
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法律資訊
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到適合的產品？
試用我們的產品選擇工具.
從最近期的版本中選擇一個：
Y K Onno Teng et al.
Arthritis and rheumatism, 56(12), 3909-3918 (2007-12-01)
Anti-CD20-mediated B cell depletion with rituximab is a new and effective therapy for rheumatoid arthritis (RA). Although B cells in peripheral blood (PB) are consistently depleted in all patients, the clinical effects are more heterogeneous, possibly related to differences in
Oliver M Steinmetz et al.
Transplantation, 84(7), 842-850 (2007-11-07)
Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently
S A Greenberg et al.
Neurology, 65(11), 1782-1787 (2005-12-14)
Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Microarray studies were performed on muscle biopsy
Miho Kimura et al.
International journal of hematology, 85(1), 41-48 (2007-01-31)
To clarify the clinicopathologic significance of a loss of CD19 expression in diffuse large B-cell lymphoma (DLBCL), we evaluated CD19 expression immunohistochemically in frozen sections from 227 patients who had received diagnoses of DLBCL according to the World Health Organization
N Masir et al.
Histopathology, 48(3), 239-246 (2006-01-25)
To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. A polyclonal antibody to the C terminus of CD19 was used to immunostain
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務